Traders sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading on Monday. $77.70 million flowed into the stock on the tick-up and $106.17 million flowed out of the stock on the tick-down, for a money net flow of $28.47 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $0.70 for the day and closed at $185.29
AMGN has been the topic of a number of research analyst reports. Vetr downgraded Amgen from a “hold” rating to a “sell” rating and set a $181.60 target price on the stock. in a report on Tuesday, March 6th. BidaskClub downgraded Amgen from a “hold” rating to a “sell” rating in a report on Saturday, March 24th. ValuEngine downgraded Amgen from a “buy” rating to a “hold” rating in a report on Monday, April 2nd. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $194.00 target price on the stock in a report on Thursday, April 5th. Finally, Barclays reduced their target price on Amgen from $190.00 to $180.00 and set an “equal weight” rating on the stock in a report on Thursday, April 5th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $195.45.
The company has a market cap of $122.61 billion, a P/E ratio of 14.76, a price-to-earnings-growth ratio of 2.30 and a beta of 1.38. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 2.14.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, April 24th. The medical research company reported $3.47 EPS for the quarter, beating the Zacks’ consensus estimate of $3.24 by $0.23. The company had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.44 billion. Amgen had a return on equity of 35.80% and a net margin of 9.67%. Amgen’s revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $3.15 EPS. equities analysts expect that Amgen, Inc. will post 13.67 EPS for the current year.
In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Thursday, April 12th. The stock was sold at an average price of $172.68, for a total transaction of $263,337.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have sold 4,575 shares of company stock valued at $809,851. 0.27% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. Ancora Advisors LLC bought a new position in shares of Amgen in the 1st quarter worth about $3,520,000. Kings Point Capital Management raised its position in shares of Amgen by 10.3% in the 4th quarter. Kings Point Capital Management now owns 17,637 shares of the medical research company’s stock worth $3,067,000 after acquiring an additional 1,653 shares in the last quarter. Modera Wealth Management LLC raised its position in shares of Amgen by 1.3% in the 4th quarter. Modera Wealth Management LLC now owns 26,252 shares of the medical research company’s stock worth $4,565,000 after acquiring an additional 331 shares in the last quarter. Sheaff Brock Investment Advisors LLC raised its position in shares of Amgen by 18.6% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 43,099 shares of the medical research company’s stock worth $7,495,000 after acquiring an additional 6,753 shares in the last quarter. Finally, AlphaStar Capital Management LLC bought a new position in shares of Amgen in the 4th quarter worth about $423,000. 78.34% of the stock is owned by institutional investors and hedge funds.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.